CD274 and non-small cell lung carcinoma: Immune checkpoint inhibitors (ICIs) targeting the programmed death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathway have been widely used and significantly improve overall survival in non-small cell lung cancer (NSCLC) [1].